Results 161 to 170 of about 20,614 (289)

Cardiac and kidney outcomes after sacubitril-valsartan therapy: recovery of cardiac function relative to kidney function decline

open access: yesKidney Research and Clinical Practice
Background Sacubitril-valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction (HFrEF). However, its long-term protective effects on cardiac function with concurrent acute kidney injury (AKI)
Hyo Jeong Kim   +5 more
semanticscholar   +1 more source

Induction of ischaemic cardiomyopathy in mice without off‐target effects

open access: yes
Experimental Physiology, EarlyView.
Mark T. Waddingham, James T. Pearson
wiley   +1 more source

The evolution of guideline-directed medical therapy among decompensated HFrEF patients in sacubitril/valsartan era: Medical expenses and clinical effectiveness

open access: hybrid, 2021
Huai-Wen Liang   +9 more
openalex   +1 more source

PCV100 Real-World IMPACT of Sacubitril/Valsartan on the Quality of Life of Heart Failure Patients in Portugal [PDF]

open access: bronze, 2020
Marta Afonso Nogueira   +9 more
openalex   +1 more source

Detection of muscular system adverse reaction signals in sacubitril/valsartan treatment combined with statins

open access: yesFrontiers in Pharmacology
ObjectiveTo detect muscular system adverse reaction signals of sacubitril/valsartan treatment combined with statins (atorvastatin, rosuvastatin, simvastatin) to provide a reference for clinical administration.MethodsMultiplicative and additive models ...
Fukun Zhao   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy